Showing posts with label clinical trial. Show all posts
Showing posts with label clinical trial. Show all posts

Tuesday, March 19, 2013

Building a culture of participation in research

By LaTese Briggs Program Analyst at FasterCures

“I have been waiting 174 days to say this: 'Good Morning America.' "

IDA MAE ASTUTE/ABC

Good Morning America anchor, Robin Roberts, made her triumphant and long awaited return to the talkshow last month after a five month recovery from a bone marrow transplant to treat myelodysplastic syndrome (MDS). The show and her fans have been celebrating and supporting Roberts’ through her courageous fight and recovery. An emotional Roberts’ thanked her fans, colleagues, and doctors for helping her through her battle with the disease, but she also took the time to thank all of the courageous people that participate in clinical trials.

“The standard treatments of today are developing because patients before you participated in clinical trials, and in a certain sense it’s our obligation as physicians and the patients of today to develop the standards of care for the patients of tomorrow.”

By participating in clinical research studies, these giving volunteers play a key role in improving the standard of care for themselves and future patients. Clinical trials are critical to bringing new drugs and interventions to patients in need. In a recent editorial by Francis Collins, Director of the National Institute of Health (NIH), he explains that the wealth of discoveries related to the genetic and environmental causes of disease, have led scientists to numerous new targets for drug development; however, the rate at which new drugs and other therapeutics are reaching patients has not increased proportionately. A key impediment to the translation of these discoveries to new treatments is the poor participation rate of Americans in clinical trials. This problem has been well-demonstrated in cancer where according to the NIH, only 3% of adults with cancer are participating in clinical trials.

According to studies conducted by CenterWatch, 94% of Americans recognize the importance of participating in clinical research in order to assist in the advancement of medical science; however, 75% of Americans state they have little to no knowledge about how clinical trials work and the participation process. This staggering statistic highlights the need to raise clinical trial awareness among the general public. Even small efforts like a simple thank you to clinical trial participants from a beloved morning show anchor, can have a major impact on achieving this goal. Thus involvement from the media and high profile individuals to illuminate the importance of clinical trials can be used as a powerful tool to educate the public on the link between improvements in healthcare and clinical research.

Educating patients and non-patients alike has become infinitely easier with the advent of online registries and databases. Sites like clinicaltrials.gov help doctors, patients, friends, and family members find clinical trials soon to be conducted in their area, their specific disease or a find a call for a person with a particular medical history.

The involvement of patient advocacy groups has also proven to be an effective way to increase clinical trial awareness and patient enrollment. A good example of this is the Love/Avon Army of Women collaboration between the Dr. Susan Love Research Foundation, the Avon Foundation, and the American Association of Cancer Research. The goal of this initiative is to recruit one million women willing to donate time, biospecimens and data to breast cancer research. To date, the organization has recruited nearly 400,000 women.

In addition, the use of outreach workers to educate patients about clinical trials can also potentially have a huge impact. These workers would not only make patients aware of clinical trials, but also work to address concerns and misconceptions about clinical trials that some may have. Common concerns include fear of experimentation, logistical concerns related to costs, insurance coverage, travel, missing work and/or time with family. Some common misconceptions are that clinical trials are last-resort efforts and one should only participate when all other approved treatments have failed, placebo treatment means that no treatment will be provided, and the assumption that intervention or treatment in the clinical trial is more invasive than standard treatment.

Clinical trials are truly the crux of drug development and medical innovation. Most trials evaluate new treatment options for safety and efficacy before making them commercially available; however, clinical trials are also used to understand the root cause of disease, improve disease detection, and compare commercially available drugs to determine which are more effective in certain patients. 

By raising awareness and educating the public about the power of clinical trials, we will be able to move research forward faster such that the many patients plagued by one disease or another will be able receive new and innovative medical solutions that hopefully exceed the current standard of care.

To find out more information about clinical trials and how you can get involved, check out these links:
-- http://clinicaltrials.gov/

FasterCures' Patients Helping Doctors (PHD) Program
The Patients Helping Doctors (PHD) program anchors everything we do at FasterCures. In fighting disease, patience is not a virtue—patients are. Through PHD, we are building a culture of participation in research where patients and healthy volunteers understand the fundamental value they bring to clinical research. We focus our efforts on unlocking patient information—medical records and biological material such as tissue, blood, and DNA—and making these available to clinical researchers in a meaningful way. Learn more here.


Thursday, March 14, 2013

Time=Lives Story of the Week: Blair Van Brunt


“Patient participation is really critical in terms of reaching for a cure, the word that nobody wants to mention by the way.”

Diagnosed at age 2 with Shwachman-Diamond Syndrome (SDS), a rare disease affecting the bone marrow, pancreas and skeleton that makes it extremely difficult to digest food and fight off infection, Blair Van Brunt’s daughter Gracie was lucky to have her biggest advocate in her corner. With determination to help find a cure, Blair, like many other parents, quickly sprung into action and became an advocate, a cheerleader and an authority on the rare disease that her now 18-year-old daughter fights every day. SDS, which is often confused with Cystic Fibrosis, is normally diagnosed in the first few years of life and slows growth dramatically.

After their daughter’s diagnosis, Blair and her husband decided to get involved with fundraising right away. Their continued passion and involvement in the cause eventually translated into Blair’s placement on the board of the Shwachman-Diamond Syndrome Foundation in 2004 and then to her current position as president, a role she’s held since 2008. Founded in 1994, the Shwachman-Diamond Syndrome Foundation is now a national voice and advocate for patients and families with SDS.

Watch Blair’s story here.

Because there are only around 1,000 cases of SDS in the United States, it is difficult to rally patients together for a clinical trial, Blair explains. “We need to populate the path [to cures] with our data, our stories, and our drive and passion to get all of us to move towards the same goal.”

Learning to embrace her disease and fight for others, Blair’s daughter Gracie uses music as both an outlet and a tribute. Make sure to check out her website and listen to some her amazing songs, like Thomas’ Song, a project she’s working on with Pledge Music where 10% of all proceeds will go to the Schwachman-Diamond Syndrome Foundation.

To learn more about SDS and the Shwachman-Diamond Syndrome Foundation, visit http://www.shwachman-diamond.org/. Or Like their Facebook page.

And make sure to check out the Time=Lives campaign to find out what you can do to help speed the medical research process.

-- VISIT the campaign Web site
-- LIKE the Facebook page
-- TWEET with us at #TimeEqLives
-- DOWNLOAD and SHARE the Message
-- TELL us your story

Tuesday, March 5, 2013

A Clinical Trials System for the 21st Century

By Samantha Mayberry, Program Assistant at FasterCures

Last month, a host of clinical trial and oncology experts at the Institute of Medicine's (IOM) “Implementing a National Cancer Clinical Trials System for the 21st Century” workshop discussed the great strides that have recently been made in the clinical trials space. The workshop, co-sponsored by the Institute of Medicine and the American Society of Clinical Oncology (ASCO), examined how the National Cancer Institute (NCI) has implemented the recommendations put forth in IOM’s 2010 report “A National Cancer Clinical Trials System for the 21st Century” with the goal of both evaluating progress against these recommendations, and identifying any outstanding gaps.

A January 2012 ASCO report details much of the progress discussed at the workshop, including the development of a centralized patient registration system amd a clinical trials data management system, as well as advancement in gaining coverage for trials through the Affordable Care Act.  However, the issues that remain clearly demonstrate that the current system is still being built to accommodate science as it was, not as it will be.

Specific issues include the fact that many NCI-run trials are not currently equipped for the rapidly-advancing science available in cancer therapeutics, particularly precision medicine, and the need for a clinical trials system run and regulated on an international scale rather than national systems for individual countries.

The NCI cooperative group program promotes and supports clinical trials for cancer therapies by coordinating researchers, cancer centers, and physicians to identify crucial issues in cancer research and design trials to answer these issues. Their goal is to make clinical trials more coordinated and efficient.


More than 30 experts from across NCI, academia, major pharmaceutical companies, cancer research institutes and biotech participated in the workshop. In a presentation to the group, FasterCures Executive Director Margaret Anderson pointed to the many innovative solutions being applied by the venture philanthropy community -- nonprofit disease research organizations that are moving away from the more conventional public charity model and instead are adopting the tools and techniques of venture capital finance, and the strategies and tactics of high-technology business management. One prime example is the Leukemia and Lymphoma Society’s Therapy Acceleration Program (TAP), which targets therapies in areas of high unmet medical need, specifically funding investigators who are performing research in those areas at all stages of clinical investigation.
 
Another trend prevalent among these organizations is the prominence of clinical trial matching tools and trial databases. Many provide opportunities for patients to register their data and/or run complete registries for trials within the disease they focus on, helping to alleviate some of the stress that academia and industry often face with patient enrollment. Finally, another unique ability of these organizations is the capacity to run clinical centers for research.

As NCI, industry, and academia seek out new models to help improve and accelerate the system, these venture philanthropies – many of whom are members of The Research Acceleration and Innovation Network (TRAIN) at FasterCures – provide a fertile nesting ground of ideas.

We look forward to seeing the official outcomes from the workshop and continuing to work with IOM and ASCO on this important issue.

Relevant Links:
• The webcast and presentations from the workshop can be found here.